William Meury Biography and Net Worth

Director of Syndax Pharmaceuticals

William Meury has served as a member of our board of directors since September 2018.

Since January 2023, Mr. Meury has served as President and Chief Executive Officer of Karuna Therapeutics, a biopharmaceutical company. From May 2020 through December 2022, Mr. Meury served as a Partner at Hildred Capital Management, a private equity firm focusing on the healthcare industry. Prior to joining Hildred Capital Management, Mr. Meury served as the Chief Commercial Officer of Allergan, plc, a global pharmaceutical company from May 2016 through its acquisition by AbbVie plc. Mr. Meury previously served as Allergan’s President, Branded Pharma from March 2015 to May 2016 and joined Allergan in July 2014 as Executive Vice President, Commercial, North American Brands. He has significant experience in launching and commercializing healthcare products. Prior to joining Allergan, Mr. Meury served as Executive Vice President, Sales and Marketing at Forest Laboratories, Inc. He joined Forest in 1993 and held multiple roles of increasing responsibility in Marketing, New Products, Business Development, and Sales. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. Mr. Meury is currently on the board of directors of Karuna Therapeutics, which is a publicly traded company, as well as on the board of directors of several private organizations.

Mr. Meury earned his B.S. in Economics from the University of Maryland.

What is William Meury's net worth?: The estimated net worth of William Meury is at least $589,440.00 as of August 2nd, 2023. Mr. Meury owns 48,000 shares of Syndax Pharmaceuticals stock worth more than $589,440 as of April 1st. This net worth estimate does not reflect any other investments that Mr. Meury may own. Learn More about William Meury's net worth.
How do I contact William Meury?: The corporate mailing address for Mr. Meury and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at ir@syndax.com. Learn More on William Meury's contact information.
Has William Meury been buying or selling shares of Syndax Pharmaceuticals?: William Meury has not been actively trading shares of Syndax Pharmaceuticals within the last three months. Most recently, William Meury sold 83,000 shares of the business's stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $20.46, for a transaction totalling $1,698,180.00. Following the completion of the sale, the director now directly owns 48,000 shares of the company's stock, valued at $982,080. Learn More on William Meury's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Neil Gallagher (President, Head of Research and Development), Keith Goldan (Chief Financial Officer), Pierre Legault (Director), Michael Metzger (COO), William Meury (Director), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. In the last year, insiders at the sold shares 3 times. They sold a total of 21,683 shares worth more than $336,086.50. The most recent insider tranaction occured on February, 10th when CFO Keith A Goldan sold 3,777 shares worth more than $58,543.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 2/10/2025.

William Meury Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/2/2023	Sell	83,000	$20.46	$1,698,180.00	48,000

William Meury Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $12.28

$12.12

$12.98

50 Day Range

MA: $14.28

$12.28

$16.38

2 Week Range

Now: $12.28

$12.06

$25.07

Volume

2,495,895 shs

Average Volume

1,513,158 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92